Grünenthal Announces Successful Completion of Phase I Trial for Investigational Compound with Potential to Become First-in-Class Therapy for Acute and Chronic Pain Aachen, Germany – Grünenthal, a global leader in pain management and related diseases, announced today the successful completion of a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.
No responses yet